Influx Healthtech Limited
Minimum investment
Bidding date
18 Jun - 20 Jun 2025
Price range
—
Minimum quantity
1,200
Minimum investment
₹1,09,200
Issue size
—
IPO doc (link)
RHP docs
Listing exchange
NSE/BSE
Influx Healthtech Limited, incorporated in September 2020, is an emerging Contract Development and Manufacturing Organization (CDMO) with a stronghold in the nutraceuticals, cosmetics, ayurvedic, and veterinary supplement sectors. Headquartered in Maharashtra, the company operates three state-of-the-art manufacturing units spread across Thane, covering 9,676 sq. ft., 13,000 sq. ft., and 14,000 sq. ft. respectively.
With a wide-ranging product portfolio that includes tablets, capsules, softgels, jellies, gummies, oral dispersible films, skincare and haircare products, the company caters to clients across various industries. Their offerings also include ayurvedic/herbal formulations, veterinary feed supplements, and homecare solutions.
Influx Healthtech stands out for its end-to-end CDMO services from R&D to manufacturing and regulatory support allowing clients to focus on brand building and distribution while relying on Influx for consistent quality and innovation. As of June 2025, the company employs 163 permanent staff and is led by an experienced team with strong technical expertise and operational excellence.
Diversified Product Portfolio: Influx Healthtech caters to a wide range of industries including nutraceuticals, cosmetics, veterinary, and homecare, offering a variety of formulations like tablets, softgels, ODFs, jellies, and personal care products. This diversification reduces dependence on any single segment.
Strong Operational Efficiency: The company boasts impressive return ratios ROCE at 49.17% and PAT margin at 12.75% indicating efficient resource utilization and healthy profitability across operations.
Experienced Leadership and Management: Led by seasoned professionals, the management team brings deep domain expertise in product development, regulatory compliance, and contract manufacturing, strengthening the company’s strategic direction.
Consistent Financial Growth: Over the last three years, Influx Healthtech has shown robust growth in revenue, assets, and net worth, highlighting sound financial management and operational scalability.
Focus on Quality and Compliance: The company maintains strict QA/QC standards across all its manufacturing units, ensuring product safety, regulatory compliance, and client trust.
SME Platform Listing: Influx Healthtech is listing on the NSE SME platform, which typically sees lower liquidity and may not attract high institutional participation, potentially affecting post-listing trading volumes.
Dependence on Key Clients: Being a CDMO, the company’s revenues depend heavily on long-term partnerships with a limited number of clients. Any disruption or loss of key accounts could impact its financial stability.
Competitive Industry Landscape: The healthcare and wellness sector is highly competitive with numerous established domestic and global players, posing pricing and market share challenges.
Regulatory Exposure: Operating in nutraceuticals, cosmetics, and veterinary health requires adherence to strict and evolving regulatory norms. Any changes in regulations may lead to operational adjustments or additional compliance costs.
Active IPOs | |
|---|---|
Company name | Bid starts |
Teamtech Formwork Solutions | 19-05-2026 |
Bio Medica Laboratories | 21-05-2026 |
Q Line Biotech | 21-05-2026 |
